Circio selected to deliver oral presentation at the prestigious ESGCT annual meeting
* An abstract submitted by Circio has been selected for an oral presentation at the ESGCT annual meeting in Hamburg, Germany, 27-30 October 2026 * ESGCT is the most important and prestigious European gene and cell therapy conference * The presentation is titled circVec: A DNA Vector Platform Harnessing Intracellular Circular RNA Biogenesis for Next-Generation T Cell Therapies' * The abstract publication date is 27 October 2026
Oslo, Norway, 6 August 2026 -- Circio Holding ASA (OSE: CRNA), a biotechnology company developing novel circular RNA expression technology for gene and cell therapy, today announces that it has been selected for an oral presentation at the European Society of Gene and Cell Therapy annual meeting in Hamburg, Germany, 27-30 October 2026.
The ESGCT Annual Meeting is the leading gene and cell therapy conference in Europe and the second largest globally, recognized as one of the most prestigious scientific meetings in the field. The meeting is widely attended by pharma industry professionals, academics, patient advocacy organizations and life science media. Only a small number of submitted abstracts are selected for oral presentation, underscoring the scientific quality and relevance of the work presented.
"ESGCT is one of the most important international meetings in the gene and cell therapy field, and it is very important for Circio that the organizing committee has selected one of Circio s abstracts for an oral presentation," said Dr. Thomas B Hansen, CTO of Circio. "Presenting our circVec platform at ESGCT provides an excellent opportunity to showcase how our proprietary DNA vector technology has the potential to significantly enhance next-generation gene and cell therapies to a highly relevant audience of life science and industry leaders. This meeting also provides an important forum to engage with existing and prospective collaborators and partners as we continue to advance our R&D programs and expand commercial opportunities."
Circio has submitted three abstracts for ESGCT 2026, of which one has been selected for oral presentation and two for poster presentation. Further information about the Circio presentations and the full abstract texts will be released on the general abstract publication date, 27 October 2026.
Presentation title: circVec: A DNA Vector Platform Harnessing Intracellular Circular RNA Biogenesis for Next-Generation T Cell Therapies
Session: Non-viral vectors/nanotechnology and RNA therapeutics I
Time & location: Wednesday 28 October at 10:00am - Hamburg, Germany
For further information, please contact: Erik Digman Wiklund, CEO Phone: +47 413 33 536 Email: erik.wiklund@circio.com
Lubor Gaal, CFO Phone: +34 683 34 3811 Email: lubor.gaal@circio.com
About Circio Building circular RNA expression systems for enhanced gene and cell therapies
Circio Holding ASA is a biotechnology company developing novel circular RNA expression technology for gene and cell therapy.
Circio has established a unique circular RNA (circRNA) vector expression technology for next generation RNA, DNA and viral therapeutics. The proprietary circVec platform is based on a modular genetic construct designed for efficient biogenesis of multifunctional circRNA inside target cells. The circVec platform has applications in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. It has demonstrated 75-fold increased RNA half-life and up to 50-fold enhanced protein expression vs. conventional mRNA-based viral and non-viral vector systems, with the potential to become a new gold-standard gene expression technology. The circVec R&D activities are being conducted by the wholly owned subsidiary Circio AB in Stockholm, Sweden.
More information: Access the news on Oslo Bors NewsWeb site